NDAINJECTIONINJECTABLEPriority Review
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Priority Review
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROSTIN F2 ALPHA (dinoprost tromethamine) is a prostaglandin F2-alpha analog administered by injection. It is used to induce labor, control postpartum hemorrhage, and manage other obstetric and gynecological conditions. The drug works by stimulating uterine contractions and enhancing myometrial sensitivity to oxytocin.
PRE_LAUNCH
Early-stage asset with limited current commercial infrastructure; career opportunities likely concentrated in launch preparation, regulatory affairs, and market access functions.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PROSTIN F2 ALPHA is a pre-launch small molecule in the obstetric space with limited current career visibility but significant near-term opportunity. Working on this product offers exposure to launch preparation, regulatory strategy, and market entry into a specialized therapeutic area with defined clinical protocols.
Regulatory Affairs SpecialistMarket Access Manager
Worked on PROSTIN F2 ALPHA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.